Chemoradiation Protocols. ??? ???????_??? ????_??????
Conditions
Interventions
Intervention 1: Patients in the arm 1 treat with the combination of cisplatin 30mg/m2 and irrinotecan 65mg/m2 days 1,8 every 3 weeks at least 2 cycles during radiotherapy and 1 cycle before and 2 cycl
Treatment - Drugs
Diagnosis
Patient in the control arme treat with the combination of paclitaxel 50mg\m2 and carboplatin AUC:2 ,weekly during radiotherapy .
Patients in the arm 1 treat with the combination of cisplatin 30mg/m2 and irrinotecan 65mg/m2 days 1,8 every 3 weeks at least 2 cycles during radiotherapy and 1 cycle before and 2 cycles after chemora
Sponsors
Vice chancellor for research, Mashhad University of Medical Sciencesice
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Iinclusion criteria:Primery Esophageal or Cardioesoohageal ?Cancer(Adenocarcinoma or Scc);Without eny distant metastas;Maximum age 75 years ;Performance Status>70% ;Hemotologically Stable; Normal liver and kidney function; Patient Satisfaction; Unfit patient for surgery. Exclusion Criteria;Metastatic disease; Cervical Esophageal Cancer; Thracheoesophageal fistula; Another previous or current malignant disease ; Any surgery performed within the past 4 weeks; According to the judgment of physition.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Survival Rate. Timepoint: 1-Every 3 monthes after start of intervention2-Following every cycle of chemothrapy. Method of measurement: 1-Monthes that patients survive after intervention2-Questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1-Disease Free Survival 2-toxcicity. Timepoint: 1-Every 3 months after start of intervention 2-Following every cycle of chemothrapy. Method of measurement: Monthes that patients survive after start of intervention-qestionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMitra Fazl Ersi
Cancer Research Center
Outcome results
None listed